QTORIN rapamycin 3.9 percent gel

Name: QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

1 evidence topic · 1 source

Preclinical evidence

“QTORIN Rapamycin Inhibits Both mTORC1 and mTORC2” (opens the source at this quote in a new tab)
“(N=8 Mice)” (opens the source at this quote in a new tab)